Showing 4411-4420 of 6036 results for "".
- Cassini Launches Cassini Connect Digital Cataract Surgery Suitehttps://modernod.com/news/cassini-launches-cassini-connect-digital-cataract-surgery-suite/2481601/Cassini announced the launch of the Cassini Connect, a digital cataract surgery suite compatible with most leading microscope brands, at the 2023 ASCRS meeting. Cassini Connect offers an integrated cataract surgery workflow and data solution, from pre-op
- Norlase Receives FDA 510(k) Clearance and CE Mark Approval For ECHO Green Pattern Laserhttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-approval-for-echo-green-pattern-laser/2481597/Norlase has received both FDA 510(k) clearance and CE Mark approval for the ECHO Green Pattern Laser photocoagulator. ECHO is a portable scanning laser photocoagulator utilizing MEMS technology. The laser and scanner are completely integrated into a single delivery device that
- Alcon Expands Plastic Bank Partnership in 2023 to Further Support Sustainability Effortshttps://modernod.com/news/alcon-expands-plastic-bank-partnership-in-2023-to-further-support-sustainability-efforts/2481591/Alcon announced the expansion of the partnership with Plastic Bank—an organization that builds recycling ecosystems in under-developed communities to fight plastic pollution while providing collection members with a path out of poverty. For each ton of plastic introduced in the marketp
- Harrow Launches Recently Acquired Products Ilevro, Nevanec, and Maxidex in the UShttps://modernod.com/news/harrow-launches-recently-acquired-products-ilevro-nevanec-and-maxidex-in-the-us/2481587/Harrow announced the completion of the transfer to Harrow of the new drug applications (NDAs) for Ilevro (nepafenac ophthalmic suspension) 0.3%, Nevanec (nepafenac ophthalmic suspension) 0.1%, and Maxidex (dexamethasone ophthalmic suspension) 0.1%. These three FDA-approved ophthalm
- Julie Schornack, OD, Named First Female President of Marshall B. Ketchum Universityhttps://modernod.com/news/julie-schornack-od-named-first-female-president-of-marshall-b-ketchum-university/2481585/Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution in Fullerton, California has introduced Julie A. Schornack, OD, MEd, as its next president to lead the university. Dr. Schornack is the first female p
- Alcon Names Daniel M. Miller, MD, PhD, Senior Scientific Advisor to Alcon's R&D team PDFhttps://modernod.com/news/alcon-names-daniel-m-miller-md-phd-senior-scientific-advisor-to-alcons-rd-team-pdf/2481584/Alcon announced that the highly esteemed ophthalmologist, Daniel M. Miller, MD, PhD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Miller is a fellowship-trained medical and surgical retina specialist. He will serve as a Senior Scientific Advisor to Alc
- BVI Completes Enrollment of Finevision HP IDE Clinical Studyhttps://modernod.com/news/bvi-completes-enrollment-of-finevision-hp-ide-clinical-study/2481581/BVI announced it has completed enrollment of its US Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal IOL, Finevision HP. The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, rand
- Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-receives-fda-clearance-of-ind-application-for-atsn-201-an-investigational-gene-therapy-for-the-treatment-of-x-linked-retinoschisis/2481580/Atsena Therapeutics, a clinical-stage gene therapy company, announced the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2 clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). ATSN-201 leverages one of the company&rsquo
- Japanese Drugmaker Astellas Pharma Acquires Iveric Bio for $5.9 Billionhttps://modernod.com/news/japanese-drugmaker-astellas-pharma-acquires-iveric-bio-for-59-billion-1/2481577/Japan-based Astellas Pharma announced it is acquiring Iveric Bio, maker of a geographic atrophy drug in late-stage development, for $5.9 billion. Under terms of the agreement, the companies entered into a definitive agreement under which Berry Merger Sub Inc., a wholly-owned subsidiary
- Lumibird Launches Tango Neo and UltraQ Reflex Neo Lasershttps://modernod.com/news/lumibird-launches-tango-neo-and-ultraq-reflex-neo-lasers/2481570/Following the launch of its flagship product, the Tango Reflex Neo, in December 2022, Lumibird Medical announced the launch of two additional variants within its premium Nd:YAG/SLT laser range—the UltraQ Reflex Neo and Tango Neo. A fully integrated Q-switched Nd:YAG lase